Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3459504 | 0.85 | HDAC4 (0.31) | HDAC4HDAC2HDAC8HDAC6 | |
| SCHEMBL16619760 | 0.79 | HDAC2 (0.42) | HDAC4HDAC2HDAC8HDAC6KDM1A | |
| SCHEMBL6833727 | 0.79 | ALDH1A1 (0.34) | HDAC4HDAC2HDAC8HDAC6KDM1A | |
| SCHEMBL5932189 | 0.72 | HDAC2 (0.44) | HDAC4HDAC2HDAC8HDAC6 | |
| SCHEMBL5932198 | 0.72 | HDAC2 (0.44) | HDAC4HDAC2HDAC8HDAC6 | |
| SCHEMBL11812421 | 0.72 | CTSK (0.34) | HDAC4HDAC2HDAC8HDAC6 | |
| SCHEMBL25095364 | 0.71 | HDAC2 (0.42) | HDAC4HDAC2HDAC8HDAC6 | |
| SCHEMBL5932677 | 0.71 | HDAC2 (0.42) | HDAC4HDAC2HDAC8HDAC6 | |
| SCHEMBL6559546 | 0.71 | HDAC4 (0.42) | HDAC4HDAC2HDAC8HDAC6 | |
| SCHEMBL5932684 | 0.71 | HDAC2 (0.42) | HDAC4HDAC2HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1680137-B1 | Macrocyclic carboxylic acid and acylsulfonamide compound as inhibitor of HCV replication | HOFFMANN LA ROCHE (CH) | 2012-11-21 | — | — | EP | disclosed |
| EP-2407470-A2 | Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication | F. Hoffmann-La Roche Ltd. (CH) | 2012-01-18 | — | — | EP | disclosed |
| EP-2390262-A1 | Synthetic chemokine receptor ligands and methods of use thereof | Intermune, Inc. (US) | 2011-11-30 | — | — | EP | disclosed |
| US-20110008289-A1 | HYPERGLYCOSYLATED POLYPEPTIDE VARIANTS AND METHODS OF USE | ALIOS BIOPHARMA, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20100099851-A1 | SYNTHETIC HYPERGLYCOSYLATED, PROTEASE-RESISTANT POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME | ALIOS BIOPHARMA, INC. (US) | 2010-04-22 | — | — | US | disclosed |
| US-20090286843-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | HOFFMANN-LA ROCHE INC. | 2009-11-19 | — | — | US | disclosed |
| US-7597884-B2 | Hyperglycosylated polypeptide variants and methods of use | ALIOS BIOPHARMA, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20090226400-A1 | CONTINUOUS DELIVERY METHODS FOR TREATING HEPATITIS VIRUS INFECTION | THREE RIVERS PHARMACEUTICALS, LLC (US) | 2009-09-10 | — | — | US | disclosed |
| EP-2093235-A1 | Hyperglycosylated variants of interferon alfacon-1 | Alios Biopharma Inc. (US) | 2009-08-26 | — | — | EP | disclosed |
| EP-1789074-A4 | SYNTHETIC HYPERGLYCOSYLATED, PROTEASE-RESISTANT POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME | ALIOS BIOPHARMA INC (US) | 2009-08-12 | — | — | EP | disclosed |
| WO-2005000227-A2 | METHODS OF TREATING TNF-MEDIATED DISORDERS | INTERMUNE, INC. (US) | 2005-01-06 | — | — | WO | disclosed |
| WO-2004110245-A2 | COMBINATION THERAPY FOR CANCER TREATMENT | INTERMUNE, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
| WO-2004105684-A2 | COMBINATION THERAPY FOR PROLIFERATIVE DISORDERS | INTERMUNE, INC. (US) | 2004-12-09 | — | — | WO | disclosed |
| WO-2004103296-A2 | METHODS OF TREATING IDIOPATHIC PULMONARY FIBROSIS | INTERMUNE, INC. (US) | 2004-12-02 | — | — | WO | disclosed |
| WO-2004089283-A2 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS | INTERMUNE, INC. (US) | 2004-10-21 | — | — | WO | disclosed |
| WO-2004078193-A1 | INTERFERON DRUG THERAPY FOR THE TREATMENT OF VIRAL DISEASES AND LIVER FIBROSIS | INTERMUNE, INC. (US) | 2004-09-16 | — | — | WO | disclosed |
| WO-2004078127-A2 | CONTINUOUS DELIVERY METHODS FOR TREATING HEPATITIS VIRUS INFECTION | INTERMUNE, INC. (US) | 2004-09-16 | — | — | WO | disclosed |
| WO-2004078207-A1 | INTERFERON DRUG THERAPY FOR THE TREATMENT OF VIRAL DISEASES AND LIVER FIBROSIS | INTERMUNE, INC. (US) | 2004-09-16 | — | — | WO | disclosed |
| WO-2004078194-A1 | INTERFERON DRUG THERAPY FOR THE TREATMENT OF VIRAL DISEASES AND LIVER FIBROSIS | INTERMUNE, INC. (US) | 2004-09-16 | — | — | WO | disclosed |
| WO-2004019863-A2 | COMBINATION THERAPY FOR TREATMENT OF FIBROTIC DISORDERS | INTERMUNE, INC. (US) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099851-A1 | SYNTHETIC HYPERGLYCOSYLATED, PROTEASE-RESISTANT POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME | IFNAR1, IDE, CTSC | HDAC4 3485/4885HDAC2 4356/4885HDAC8 3338/4885 |
| US-20090286843-A1 | MACROCYCLIC COMPOUNDS AS INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, ZC3HAV1 | HDAC4 2107/4885HDAC2 1507/4885HDAC8 2090/4885 |
| US-20110008289-A1 | HYPERGLYCOSYLATED POLYPEPTIDE VARIANTS AND METHODS OF USE | IFNAR1, EPOR, HBB | HDAC4 4489/4885HDAC2 4845/4885HDAC8 4480/4885 |
| US-20090226400-A1 | CONTINUOUS DELIVERY METHODS FOR TREATING HEPATITIS VIRUS INFECTION | IFNG, HAVCR2, IFNAR1 | HDAC4 948/4885HDAC2 2293/4885HDAC8 2515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.